Level D· Scientific groundwork from lab and animal studiesLaboratory StudyEurope PMCOpen access

Emerging concepts in osteoarthritis and musculoskeletal diseases: Insights from the University of Debrecen Musculoskeletal Symposium 2025

Kovács P., Vágó J., Mobasheri A., Jenei-Lanzl Z., Zaucke F., Madry H.

Laboratory Study on Osteoarthritis, Disc Degeneration, Immune Modulation, Autoimmune Research, published in Osteoarthr Cartil Open (2026) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
Osteoarthr Cartil Open (2026)
Reported sample size
—
Source database
Europe PMC
PMID
41550415
PMCID
PMC12803891
DOI
10.1016/j.ocarto.2025.100728

Abstract (original English)

Objective To highlight the key translational advances and interdisciplinary discussions from the 2025 University of Debrecen Musculoskeletal Symposium (UD-MUSK), focusing on osteoarthritis (OA) and related musculoskeletal (MSK) diseases. Method The UD-MUSK Symposium convened international and local experts for keynote presentations and scientific dialogue spanning OA and MSK disease mechanisms, translational therapies, and tissue regeneration. Core topics included extracellular matrix (ECM) remodelling, cell/gene therapies, animal disease models, chronic stress, autoimmunity, immunotherapies, and muscle and stem cell biology, reflecting the Symposium's broad interdisciplinary spectrum. Results ECM proteomics revealed degradation fragments that act as drivers and potential modulators of OA, offering new biomarkers and therapeutic targets. Advances in cell- and gene-based therapies were presented, including the use of growth differentiation factor 6 (GDF6) and CRISPR approaches for cartilage and intervertebral disc repair. Large animal models simulating spatio-temporal changes in human OA, and studies demonstrating chronic stress-accelerated OA via neuroendocrine mechanisms, were highlighted. Novel strategies in immune modulation, such as chimeric antigen receptor (CAR) T cell therapy for autoimmune myopathies, alongside research on muscle regeneration and circadian regulation by

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research